The National Institute of Neurological Disorders and Stroke (NINDS) provides funding (approximately $100 million annually) and resources through grants, cooperative agreements, and contracts to industry and university researchers to advance early-stage neurological technologies, devices and therapeutic programs to industry adoption (i.e., investor funding and corporate partnerships). The presentation will cover challenges and opportunities in translating viable ideas from bench to bedside to treat neurological disorders and stroke with the special emphasis on the value of preclinical animal models and considerations for pharmacodynamics measures.

Biography

Amir Tamiz is a Program Director at the National Institute of Neurological Disorders and Stroke (NINDS), Office of Translational Research (OTR) who oversees NIH Blueprint Neurotherapeutics network (BPN) and Innovation Grants to Nurture Initial Translational Efforts (IGNITE). Prior to joining NIH in 2012, he had held scientific and management positions in research and development of therapeutic programs at Corvas International (acquired by Dendreon), CovX (now part of Pfizer) and Alba Therapeutics. He received his PhD at University of Oregon and conducted Post-doctoral research at the Department of Neuroscience at Georgetown University Medical Center.

Notes: